Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly EBITDA Margin of 244.88% for Q1 2026, up 9189.0% year-over-year from 2.64% in Q1 2025, and up 92.82% quarter-over-quarter from 3411.01% in Q4 2025.
Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported EBITDA Margin for 8 consecutive years, with 244.88% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 9189.0% year-over-year to 244.88%; the TTM figure through Mar 2026 stood at 697.67% (down 22518.0% YoY), while the FY2025 annual figure was 891.07%, down 33526.0% from the prior year.
- EBITDA Margin climbed to 244.88% in Q1 2026 per KYMR's latest filing, from 3411.01% in the prior quarter.
- Across five years, EBITDA Margin topped out at 40.33% in Q4 2023 and bottomed at 3411.01% in Q4 2025.
- Historically, EBITDA Margin has averaged 900.2% across 5 years, with a median of 469.92% in 2022.
- On a YoY basis, EBITDA Margin climbed as much as 22541 bps in 2025 and fell as far as 231884 bps in 2025.
- Kymera Therapeutics' EBITDA Margin stood at 239.36% in 2022, then soared by 83 bps to 40.33% in 2023, then slumped by 2608 bps to 1092.17% in 2024, then sank by 212 bps to 3411.01% in 2025, then soared by 93 bps to 244.88% in 2026.
- Business Quant data shows KYMR's EBITDA Margin at 244.88% in Q1 2026, 3411.01% in Q4 2025, and 3347.36% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -116.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -116.32% |
| Mar 31, 2026 | -244.88% |
| Dec 31, 2025 | -3,411.01% |
| Sep 30, 2025 | -3,347.36% |
| Jun 30, 2025 | -736.82% |
| Mar 31, 2025 | -336.77% |
| Dec 31, 2024 | -1,092.17% |
| Sep 30, 2024 | -1,927.93% |
| Jun 30, 2024 | -198.54% |
| Mar 31, 2024 | -562.18% |
| Dec 31, 2023 | -40.33% |
| Sep 30, 2023 | -1,216.35% |
| Jun 30, 2023 | -262.72% |
| Mar 31, 2023 | -478.83% |
| Dec 31, 2022 | -239.36% |
| Sep 30, 2022 | -469.92% |
| Jun 30, 2022 | -354.44% |
| Mar 31, 2022 | -383.84% |
| Dec 31, 2021 | -222.55% |
| Sep 30, 2021 | -140.82% |